 support broad population screening
of asymptomatic patients for PAD. However, future
studies may identify targeted subgroups of patients,
particularly those not yet on cardioprotective treatment
regimens (eg, patients with diabetes alone, hypertension
alone, or advanced age without clinically evident cardiovascular disease) that may beneﬁt from PAD screening to
trigger more aggressive medical management. To date,
inadequate data exist to deﬁne these speciﬁc subgroups,
and broad population screening